Tygacil Side Effects Require Black Box Warnings, Petition to FDA Claims

The prominent consumer advocacy group Public Citizen is calling for the FDA to require a new black box warning for the antibiotic Tygacil, indicating that the drug carries a higher mortality rate when compared to other antibiotics. 

A petition for a Tygacil black box warning was filed with the FDA last week, suggesting that the strongest label warning possible should be added to Tygacil because current mortality risk information on the label is inadequate.

Public Citizen also wants the FDA to require that a medication guide be given to patients and that the agency send out a “Dear Doctor” letter clarifying the potential risk of Tygacil side effects for physicians.

Did You Know?

Millions of Philips CPAP Machines Recalled

Philips DreamStation, CPAP and BiPAP machines sold in recent years may pose a risk of cancer, lung damage and other injuries.

Learn More

The black box warning should alert users to the fact that there is an increased risk of death when using Tygacil, Public Citizen said in a letter (pdf) to FDA Commissioner Margaret A. Hamburg and Center for Drug Evaluation and Research Director Janet Woodcock. The Tygacil black box warning should also indicate that the drug is an antibiotic of last-resort after other treatments have failed, and should only be used in combination with one or more antibacterial antibiotics, the group urged.

Tygacil (tigecycline) was approved by FDA for the treatment of certain types of infections in June 2005. Created by Wyeth, which is now owned by Pfizer, Inc., the drug is approved to treat complicated skin infections, intra-abdominal infections, and community-acquired pneumonia. It is not approved for the treatment of hospital-acquired pneumonia (including ventilator-associated pneumonia).

In September 2010, the FDA issued a Tygacil safety alert after analyzing a number of clinical trials that indicated that the mortality rate with Tygacil was higher when treating all types of infections, but particularly when treating ventilator-associated pneumonia. Patients given Tygacil to treat pneumonia had a 20% chance of dying, compared to only 12% from competing antibiotics. The agency required new information on the mortality rate be added to the drug’s label, but Public Citizen officials called those label changes “woefully inadequate.”

Hospital-acquired pneumonia is a common risk for critically ill patients, particularly those on ventilators. Contraction of pneumonia puts critically ill patients at a 20 to 30 percent risk of death, and can increase a patient’s hospital stay by seven to nine days, potentially exposing them to other complications. Pneumonia usually occurs because stomach secretions have entered the lungs.


"*" indicates required fields

Share Your Comments

I authorize the above comments be posted on this page*

Have Your Comments Reviewed by a Lawyer

Provide additional contact information if you want an attorney to review your comments and contact you about a potential case. This information will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Philips CPAP Lawsuit Filing Deadlines May Be Approaching in Some Claims
Philips CPAP Lawsuit Filing Deadlines May Be Approaching in Some Claims (Posted 2 days ago)

Lawyers are working to register and file Philips CPAP lawsuits, as the manufacturer may argue the June 14 anniversary of a massive recall triggered the start of the statute of limitations in certain states